Geode Capital Management LLC Increases Stock Holdings in Pulse Biosciences, Inc. (NASDAQ:PLSE)

Geode Capital Management LLC boosted its holdings in shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) by 7.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 457,165 shares of the company’s stock after buying an additional 33,200 shares during the period. Geode Capital Management LLC’s holdings in Pulse Biosciences were worth $8,020,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in PLSE. State Street Corp raised its holdings in shares of Pulse Biosciences by 17.8% in the third quarter. State Street Corp now owns 461,333 shares of the company’s stock worth $8,092,000 after buying an additional 69,696 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Pulse Biosciences by 193.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock valued at $2,598,000 after acquiring an additional 97,565 shares during the period. Bank of New York Mellon Corp raised its stake in Pulse Biosciences by 23.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock worth $570,000 after acquiring an additional 9,639 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Pulse Biosciences during the 3rd quarter worth about $588,000. Finally, Barclays PLC grew its stake in Pulse Biosciences by 361.4% during the 3rd quarter. Barclays PLC now owns 30,306 shares of the company’s stock valued at $530,000 after purchasing an additional 23,738 shares during the last quarter. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Burke Thomas Barrett sold 50,000 shares of the company’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total transaction of $871,000.00. Following the completion of the sale, the chief executive officer now owns 63,172 shares of the company’s stock, valued at approximately $1,100,456.24. This represents a 44.18 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Robert W. Duggan purchased 56,054 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The stock was bought at an average cost of $17.35 per share, with a total value of $972,536.90. Following the acquisition, the director now owns 42,228,057 shares of the company’s stock, valued at approximately $732,656,788.95. The trade was a 0.13 % increase in their position. The disclosure for this purchase can be found here. 71.50% of the stock is owned by company insiders.

Pulse Biosciences Trading Up 2.2 %

Shares of Pulse Biosciences stock opened at $17.79 on Friday. Pulse Biosciences, Inc. has a fifty-two week low of $6.59 and a fifty-two week high of $22.69. The firm has a 50-day simple moving average of $18.02 and a two-hundred day simple moving average of $16.90.

Pulse Biosciences (NASDAQ:PLSE) last released its earnings results on Wednesday, October 30th. The company reported ($0.21) EPS for the quarter. During the same period last year, the firm earned ($0.19) EPS.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of Pulse Biosciences to a “sell” rating in a research note on Thursday.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.